This trial is a single arm, two cohorts, phase II study. All patients are stage IIIB-IV
NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-1 and no sensitizing
mutation of the epidermal growth factor receptor gene or translocation of the anaplastic
lymphoma kinase gene. Cohort 1 includes patients with metastatic or recurrent NSCLC after
progression on treatment with platinum-based chemotherapy and PD-1/PD-L1, given concurrently
or sequentially. Cohort 2 includes treatment naïve patients with advanced NSCLC. All patients
will recieve AK104 15mg/kg every 3 weeks(for up to 2 years) and anlotinib(12mg/d). The
primary end point are objective response rate per RECIST1.1 and safety. Secondary end points
are progression-free survival and overall survival.